B-cell abnormalities and impact on antibody response in HIV infection

Current Opinion in HIV and AIDS

Volumn 12, Issue 3, 2017, Pages 203-208

  Noto, Alessandra ^a   Pantaleo, Giuseppe ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Broadly neutralizing antibodies; Germinal center B cells; HIV 1 infection; T follicular helper cells

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY RESPONSE; B LYMPHOCYTE; GERMINAL CENTER; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTIBODY PRODUCTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 85013115160     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000359     Document Type: Review

References (74)

1. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1, Nature 2003; 422:307-312.
2. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100:4144-4149.
3. Gray ES, Moore PL, Choge IA, et al., CAPRISA 002 Study Team. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007; 81:6187-6196.
4. Mikell I, Sather DN, Kalams SA, et al. Characteristics of the earliest crossneutralizing antibody response to HIV-1. PLoS Pathog 2011; 7:e1001251.
5. Tomaras GD, Binley JM, Gray ES, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 2011; 85:11502-11519.
6. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252.
7. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034.
8. Sather DN, Armann J, Ching LK, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83:757-769.
9. Stamatatos L, Morris L, Burton DR, Mascola J.R.. Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine Nat Med 2009; 15:866-870.
10. Doria-Rose NA, Klein RM, Daniels MG, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: Clustering analysis and association with clinical variables. J Virol 2010; 84:1631-1636.
11. Walker LM, Simek MD, Priddy F, et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010; 6:e1001028.
12. Gray ES, Madiga MC, Hermanus T, et al., CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4\+ T cell decline and high viral load during acute infection. J Virol 2011; 85:4828-4840.
13. Verkoczy L, Kelsoe G, Moody MA, Haynes BF. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 2011; 23:383-390.
14. Basten A, Silveira PA. B-cell tolerance: Mechanisms and implications. Curr Opin Immunol 2010; 22:566-574.
15. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008; 20:632-638.
16. Verkoczy L, Diaz M, Holl TM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010; 107:181-186.
17. Walker LM, Phogat SK, Chan-Hui PY, et al., Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
18. Walker LM, Huber M, Doores KJ, et al., Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
19. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633-1637. doi:10. 1126/science. 1207227.
20. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-861.
21. Mouquet H, Scharf L, Euler Z, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 2012; 109:E3268-E3277.
22. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491:406-412.
23. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-476.
24. Huang J, Kang BH, Pancera M, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014; 515:138-142.
25. Mascola J.R., Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
26. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
27. Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(-mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87:1708-1719.
28. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108:11181-11186.
29. Moldt B, Rakasz EG, Schultz N, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012; 109:18921-18925.
30. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
31. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015; 522:487-491.
32. Scheid JF, Horwitz JA, Bar-On Y, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 2016; 535:556-560.
33. Caskey M, Schoofs T, Gruell H, et al. Antibody 10-1074 suppresses viremia in HIV-1 infected individuals. Nat Med 2017. doi:10. 1038/nm4268.
34. Gautam R, Nishimura Y, Pegu A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 2016; 533:105-109.
35. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-122.
36. Bar KJ, Sneller MC, Harrison LJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 2016; 375:2037-2050.
37. Burton DR, Mascola J.R.. Antibody responses to envelope glycoproteins in HIV-1 infection. Nature Immunol 2015; 16:571-576.
38. Burton DR, Ahmed R, Barouch DH, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012; 12:396-407.
39. Moore PL, Williamson C, Morris L. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol 2015; 23:204-211.
40. Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153:126-138.
41. Kwong PD, Mascola J.R.. Human antibodies that neutralize HIV-1: Identification, structures, B cell ontogenies. Immunity 2012; 37:412-425.
42. Rusert P, Kouyos RD, Kadelka C, et al. Determinants of HIV-1 broadly neutralizing antibody induction. Nat Med 2016; 22:1260-1267.
43. Goo L, Chohan V, Nduati R, Overbaugh J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 2014; 20:655-658.
44. Landais E, Huang X, Havenar-Daughton C, et al. Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. PLoS Pathog 2016; 12:e1005369.
45. Ranasinghe S, Soghoian DZ, Lindqvist M, et al. HIV-1 antibody neutralization breadth is associated with enhanced HIV-specific CD4\+ T cell responses. J Virol 2015; 90:2208-2220.
46. Cohen K, Altfeld M, Alter G, Stamatatos L. Early preservation of CXCR5\+ PD-1\+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronicHIV-1 infection. J Virol 2014; 88:13310-13321.
47. Escolano A, Steichen JM, Dosenovic P, et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 2016; 166:1445-1458.
48. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev 2013; 254:207-224.
49. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: Correlation with increased IL-7, Proc Natl Acad Sci USA, 2006, 103. 2262-2267
50. Malaspina A, Moir S, Chaitt DG, et al. Idiopathic CD4\+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 2007; 109:2086-2088.
51. Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA 2001; 98:10362-10367.
52. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008; 205:1797-1805.
53. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-245.
54. Malaspina A, Moir S, DiPoto AC, et al. CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV-infected individuals. J Immunol 2008; 181:1199-1206.
55. Jiang W, Lederman MM, Mohner RJ, et al. Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol 2008; 82:7837-7845.
56. De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180-2186.
57. Schnittman SM, Lane HC, Higgins SE, et al. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 1986; 233:1084-1086.
58. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992; 89:561-566.
59. Kardava L, Moir S, Shah N, et al. Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. J Clin Invest 2014; 124:3252-3262.
60. Buckner CM, Kardava L, Zhang X, et al. Maintenance of HIV-specific memory B-cell responses in elite controllers despite low viral burdens. J Infect Dis 2016; 214:390-398.
61. Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, production. J Exp Med 2013; 210:143-156.
62. Havenar-Daughton C, Carnathan DG, Torrents de la Penã A, et al. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer. Cell Rep 2016; 17:2195-2209.
63. Kim CH, Rott LS, Clark-Lewis I, et al. Subspecialization of CXCR5\+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5\+ T cells. J Exp Med 2001; 193:1373-1381.
64. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, support immunoglobulin production. J Exp Med 2000; 192:1545-1552.
65. Schaerli P, Willimann K, Lang AB, et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192:1553-1562.
66. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: Lineage and location. Immunity 2009; 30:324-335.
67. Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol 2009; 10:375-384.
68. Lindqvist M, van Lunzen J, Soghoian DZ, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012; 122:3271-3280.
69. Cubas RA, Mudd JC, Savoye AL, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013; 19:494-499.
70. Cubas R, Perreau M. The dysfunction of T follicular helper cells. CurrOpin HIV AIDS 2014; 9:485-491.
71. Cubas R, van Grevenynghe J, Wills S, et al. Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection. J Immunol 2015; 195:5625-5636.
72. Velu V, Mylvaganam GH, Gangadhara S, et al. Induction of Th1-biased T follicular helper (Tfh) cells in lymphoid tissues during chronic simian immunodeficiency virus infection defines functionally distinct germinal center Tfh cells. J Immunol 2016; 197:1832-1842.
73. Kim JR, Lim HW, Kang SG, et al. Human CD57\+ germinal center-T cells are the major helpers for GC-B cells and induce class switch recombination. BMC Immunol 2005; 6:3.
74. Yamamoto T, Lynch RM, Gautam R, et al. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci Transl Med 2015; 7:298ra120. doi:10. 1126/scitranslmed. aab3964.